AAAAAA

   
Results: 1-9 |
Results: 9
Metabolism and renal clearance of In-111-labeled DOTA-conjugated antibody fragments
Authors: Tsai, SW Li, L Williams, LE Anderson, AL Raubitschek, A Shively, JE
Citation: Sw. Tsai et al., Metabolism and renal clearance of In-111-labeled DOTA-conjugated antibody fragments, BIOCONJ CHE, 12(2), 2001, pp. 264-270
An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA
Authors: Lewis, MR Kao, JY Anderson, ALJ Shively, JE Raubitschek, A
Citation: Mr. Lewis et al., An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA, BIOCONJ CHE, 12(2), 2001, pp. 320-324
Human T lymphocyte genetic modification with naked DNA
Authors: Jensen, MC Clarke, P Tan, G Wright, C Wen, CC Clark, TN Zhang, FY Slovak, ML Wu, AM Forman, SJ Raubitschek, A
Citation: Mc. Jensen et al., Human T lymphocyte genetic modification with naked DNA, MOL THER, 1(1), 2000, pp. 49-55
Phase I/II Y-90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
Authors: Wiseman, GA White, CA Stabin, M Dunn, WL Erwin, W Dahlbom, M Raubitschek, A Karvelis, K Schultheiss, T Witzig, TE Belanger, R Spies, S Silverman, DHS Berlfein, JR Ding, E Grillo-Lopezs, AJ
Citation: Ga. Wiseman et al., Phase I/II Y-90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma, EUR J NUCL, 27(7), 2000, pp. 766-777
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a Y-90-labeled anti-CD20 monoclonal antibody
Authors: Wiseman, GA White, CA Witzig, TE Gordon, LI Emmanouilides, C Raubitschek, A Janakiraman, N Gutheil, J Schilder, RJ Spies, S Silverman, DHS Grillo-Lopez, AJ
Citation: Ga. Wiseman et al., Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a Y-90-labeled anti-CD20 monoclonal antibody, CLIN CANC R, 5(10), 1999, pp. 3281S-3286S
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsedor refractory CD20(+) B-cell non-Hodgkin's lymphoma
Authors: Witzig, TE White, CA Wiseman, GA Gordon, LI Emmanouilides, C Raubitschek, A Janakiraman, N Gutheil, J Schilder, RJ Spies, S Silverman, DHS Parker, E Grillo-Lopez, AJ
Citation: Te. Witzig et al., Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsedor refractory CD20(+) B-cell non-Hodgkin's lymphoma, J CL ONCOL, 17(12), 1999, pp. 3793-3803
A chimeric anti-CEA antibody with heavy interchain disulfide bonds deleted: Molecular characterization and biodistributions in normal and tumor bearing mice
Authors: Neumaier, M Gaida, FJ Lewis, MR Hefta, LJ Shively, LE Raubitschek, A Shively, JE
Citation: M. Neumaier et al., A chimeric anti-CEA antibody with heavy interchain disulfide bonds deleted: Molecular characterization and biodistributions in normal and tumor bearing mice, ANTICANC R, 19(1A), 1999, pp. 13-21
Similarities and differences in In-111- and Y-90-labeled 1B4M-DTPA antiTacmonoclonal antibody distribution
Authors: Carrasquillo, JA White, JD Paik, CH Raubitschek, A Le, N Rotman, M Brechbiel, MW Gansow, OA Top, LE Perentesis, P Reynolds, JC Nelson, DL Waldmann, TA
Citation: Ja. Carrasquillo et al., Similarities and differences in In-111- and Y-90-labeled 1B4M-DTPA antiTacmonoclonal antibody distribution, J NUCL MED, 40(2), 1999, pp. 268-276
Clinical status and optimal use of rituximab for B-cell lymphomas - The McLaughlin et al article reviewed
Authors: Raubitschek, A
Citation: A. Raubitschek, Clinical status and optimal use of rituximab for B-cell lymphomas - The McLaughlin et al article reviewed, ONCOLOGY-NY, 12(12), 1998, pp. 1775-1776
Risultati: 1-9 |